Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Equity Average (2019 - 2025)

Keros Therapeutics filings provide 7 years of Equity Average readings, the most recent being $503.4 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 8.84% to $503.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $503.4 million, a 8.84% decrease, with the full-year FY2025 number at $437.3 million, down 3.22% from a year prior.
  • Equity Average hit $503.4 million in Q4 2025 for Keros Therapeutics, down from $705.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $717.8 million in Q2 2025 to a low of $217.4 million in Q2 2022.
  • Median Equity Average over the past 5 years was $315.1 million (2023), compared with a mean of $380.4 million.
  • Biggest five-year swings in Equity Average: soared 1251.11% in 2021 and later dropped 10.19% in 2022.
  • Keros Therapeutics' Equity Average stood at $230.8 million in 2021, then rose by 12.3% to $259.2 million in 2022, then rose by 21.14% to $314.0 million in 2023, then surged by 75.84% to $552.2 million in 2024, then decreased by 8.84% to $503.4 million in 2025.
  • The last three reported values for Equity Average were $503.4 million (Q4 2025), $705.2 million (Q3 2025), and $717.8 million (Q2 2025) per Business Quant data.